Singh Jaspreet, Singh Sanjeev
School of Bioengineering & Biosciences, Lovely Professional University, 15935, Block 56, Room No 202, Phagwara, Punjab 144411 India.
Ren Replace Ther. 2023;9(1):21. doi: 10.1186/s41100-023-00475-2. Epub 2023 Apr 27.
Renal disorders are an emerging global public health issue with a higher growth rate despite progress in supportive therapies. In order to find more promising treatments to stimulate renal repair, stem cell-based technology has been proposed as a potentially therapeutic option. The self-renewal and proliferative nature of stem cells raised the hope to fight against various diseases. Similarly, it opens a new path for the treatment and repair of damaged renal cells. This review focuses on the types of renal diseases; acute and chronic kidney disease-their statistical data, and the conventional drugs used for treatment. It includes the possible stem cell therapy mechanisms involved and outcomes recorded so far, the limitations of using these regenerative medicines, and the progressive improvement in stem cell therapy by adopting approaches like PiggyBac, Sleeping Beauty, and the Sendai virus. Specifically, about the paracrine activities of amniotic fluid stem cells, renal stem cells, embryonic stem cells, mesenchymal stem cell, induced pluripotent stem cells as well as other stem cells.
尽管支持性治疗取得了进展,但肾脏疾病仍是一个正在出现的全球公共卫生问题,且增长率更高。为了找到更有前景的治疗方法来刺激肾脏修复,基于干细胞的技术已被提出作为一种潜在的治疗选择。干细胞的自我更新和增殖特性带来了对抗各种疾病的希望。同样,它为受损肾细胞的治疗和修复开辟了一条新途径。本综述重点关注肾脏疾病的类型;急性和慢性肾病——它们的统计数据,以及用于治疗的传统药物。它包括目前涉及的可能的干细胞治疗机制和记录的结果、使用这些再生药物的局限性,以及通过采用诸如猪尾巴病毒载体、睡美人转座子系统和仙台病毒等方法在干细胞治疗方面取得的逐步进展。具体而言,涉及羊水干细胞、肾干细胞、胚胎干细胞、间充质干细胞、诱导多能干细胞以及其他干细胞的旁分泌活性。